Minnesota Oncology — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$156,262	12
2024	Research	$5,771	10
2023	Research	$114,882	18
2022	Research	$20,941	5
2021	Research	$29,406	12
2020	Research	$62,534	81
2019	Research	$66,275	67

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $299,280 40 payments
Eisai Inc. $107,830 119 payments
Janssen Research & Development, LLC $21,805 32 payments
Novartis Pharmaceuticals Corporation $14,939 8 payments
Pharmacyclics LLC, An AbbVie Company $12,217 6 payments

Studies the money was for Research payments · program years 2019–2025

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $117,778 1 payment
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) $106,874 118 payments
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community $95,098 15 payments
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer $25,014 8 payments
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer $15,722 30 payments
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer $12,217 6 payments
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) $10,759 1 payment
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer $9,725 1 payment
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) $9,350 4 payments
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer $8,840 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.